An observational study in ACE-I and ARB-induced Angioedema., sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-11.
Sponsored by Hospices Civils de Lyon · Observational
Specific treatments for angiotensin-converting-enzyme inhibitor (ACE-I) and angiotensin-receptor-blocker (ARB)-induced angioedema exist. Early access to these treatments is challenging because they are expensive and have short shelf lives making it illusory that all emergency department (ED) stock them. The aim of this retrospective study was to define, for each patient with a confirmed ACE-I or ARB-induced angioedema, at which step of the care, the specific treatment was administered. The second objective was to analyse the availability of these treatment in the area around Lyon, France and the factors that may influence it.
165 studies on the registry are indexed under Angioedema; 19 are open to participants now.
This study's enrollment of 38 is below the median of 158 across 45 observational studies indexed under Angioedema.
Browse Angioedema studies →Hospices Civils de Lyon is the lead sponsor of 1,856 studies on the registry; 442 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated with a specific treatment for bradykinin-mediated angioedema for a severe attack of angioedema due to ACE-inhibitors or ARB during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Patients which received no specific treatment (icatibant, C1-inhibitor concentrate) were excluded.
Step of the care allowing the patients to benefit from a specific treatment.
Three answers are possible. Patients were treated with the specific medication (icatibant or C1-inhibitor concentrate) either in the first ED or by the medical ambulance team, or by the investigators reference center's intensive care unit.
Time frame: October 2010 to December 2014
Epidemiological characteristics
The investigators collect data such as age, sex, localization of the angioedema.
Time frame: October 2010 to December 2014
Triggering treatments
The investigators detail which ACE-inhibitor, which ARB and eventually which co-medication was taken and triggered the angioedema.
Time frame: October 2010 to December 2014
The record gives a start of Feb 2016, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.